CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The new online Learning Center with new content can still be found under the “Training” folder on ...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...